Cantor Fitzgerald initiated coverage on Asensus Surgical with a new price target
$ASXC
Medical/Dental Instruments
Health Care
Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/8/2022 | $1.50 | Overweight | Cantor Fitzgerald |
| 9/8/2022 | $1.50 | Buy | Stifel |
15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub
RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately